西村 知泰 (ニシムラ トモヤス)

Nishimura, Tomoyasu

写真a

所属(所属キャンパス)

研究所・センター等 保健管理センター (日吉)

職名

准教授

外部リンク

経歴 【 表示 / 非表示

  • 2000年05月
    -
    2002年04月

    慶應義塾大学医学部, 内科学, 研修医

  • 2002年05月
    -
    2003年05月

    川崎市立川崎病院, 内科, 医員

  • 2003年06月
    -
    2004年05月

    水戸赤十字病院, 内科, 医員

  • 2004年06月
    -
    2010年01月

    慶應義塾大学医学部, 内科学(呼吸器), 助手

  • 2007年01月
    -
    2010年01月

    慶應義塾大学医学部, 微生物学・免疫学, 研究員

全件表示 >>

学歴 【 表示 / 非表示

  • 2000年03月

    慶應義塾大学, 医学部, 医学科

    大学, 卒業

学位 【 表示 / 非表示

  • 博士, 慶應義塾大学, 論文, 2008年06月

免許・資格 【 表示 / 非表示

  • 医師免許, 2000年04月

 

研究分野 【 表示 / 非表示

  • ライフサイエンス / 呼吸器内科学

  • ライフサイエンス / 感染症内科学

研究キーワード 【 表示 / 非表示

  • 抗酸菌症

 

著書 【 表示 / 非表示

  • EBM呼吸器疾患の治療2016-2017

    西村 知泰, 中外医学社, 2016年01月

    担当範囲: Interferon Gamma Release Assayの有用性は?

  • 新 呼吸器専門医テキスト

    西村 知泰, 南江堂, 2015年04月

    担当範囲: 肺結核症

  • 内科研修マニュアル 改訂第2版

    西村 知泰, 南江堂, 2006年07月

    担当範囲: 市中肺炎/院内肺炎

論文 【 表示 / 非表示

  • The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force

    Wang Q.S., Edahiro R., Namkoong H., Hasegawa T., Shirai Y., Sonehara K., Tanaka H., Lee H., Saiki R., Hyugaji T., Shimizu E., Katayama K., Kanai M., Naito T., Sasa N., Yamamoto K., Kato Y., Morita T., Takahashi K., Harada N., Naito T., Hiki M., Matsushita Y., Takagi H., Ichikawa M., Nakamura A., Harada S., Sandhu Y., Kabata H., Masaki K., Kamata H., Ikemura S., Chubachi S., Okamori S., Terai H., Morita A., Asakura T., Sasaki J., Morisaki H., Uwamino Y., Nanki K., Uchida S., Uno S., Nishimura T., Ishiguro T., Isono T., Shibata S., Matsui Y., Hosoda C., Takano K., Nishida T., Kobayashi Y., Takaku Y., Takayanagi N., Ueda S., Tada A., Miyawaki M., Yamamoto M., Yoshida E., Hayashi R., Nagasaka T., Arai S., Kaneko Y., Sasaki K., Tagaya E., Kawana M., Arimura K., Takahashi K., Anzai T., Ito S., Endo A., Uchimura Y., Miyazaki Y., Honda T., Tateishi T., Tohda S., Ichimura N., Sonobe K., Sassa C.T., Nakajima J., Nakano Y., Nakajima Y., Anan R., Arai R., Kurihara Y., Harada Y., Nishio K., Ueda T., Azuma M., Saito R., Sado T., Miyazaki Y., Sato R., Haruta Y., Nagasaki T., Yasui Y., Hasegawa Y., Mutoh Y., Kimura T., Sato T.

    Nature Communications (Nature Communications)  13 ( 1 )  2022年12月

     概要を見る

    Coronavirus disease 2019 (COVID-19) is a recently-emerged infectious disease that has caused millions of deaths, where comprehensive understanding of disease mechanisms is still unestablished. In particular, studies of gene expression dynamics and regulation landscape in COVID-19 infected individuals are limited. Here, we report on a thorough analysis of whole blood RNA-seq data from 465 genotyped samples from the Japan COVID-19 Task Force, including 359 severe and 106 non-severe COVID-19 cases. We discover 1169 putative causal expression quantitative trait loci (eQTLs) including 34 possible colocalizations with biobank fine-mapping results of hematopoietic traits in a Japanese population, 1549 putative causal splice QTLs (sQTLs; e.g. two independent sQTLs at TOR1AIP1), as well as biologically interpretable trans-eQTL examples (e.g., REST and STING1), all fine-mapped at single variant resolution. We perform differential gene expression analysis to elucidate 198 genes with increased expression in severe COVID-19 cases and enriched for innate immune-related functions. Finally, we evaluate the limited but non-zero effect of COVID-19 phenotype on eQTL discovery, and highlight the presence of COVID-19 severity-interaction eQTLs (ieQTLs; e.g., CLEC4C and MYBL2). Our study provides a comprehensive catalog of whole blood regulatory variants in Japanese, as well as a reference for transcriptional landscapes in response to COVID-19 infection.

  • Osteoporosis in nontuberculous mycobacterial pulmonary disease: a cross-sectional study

    Tanaka H., Asakura T., Suzuki S., Okamori S., Kusumoto T., Ogawa T., Uno S., Morita A., Lee H., Namkoong H., Kamata H., Sato Y., Uwamino Y., Nishimura T., Ishii M., Fukunaga K., Hasegawa N.

    BMC Pulmonary Medicine (BMC Pulmonary Medicine)  22 ( 1 )  2022年12月

     概要を見る

    Background: Since nontuberculous mycobacterial pulmonary disease (NTM-PD) is common in middle-aged/elderly slender women at risk of osteoporosis, we hypothesized that NTM-PD could be associated with osteoporosis. The study aimed to evaluate the prevalence of osteoporosis in patients with NTM-PD compared with that in the general population and determine the factors associated with osteoporosis in the subjects, including the serum estradiol (E2) and 25-hydroxyvitamin D (25OHD) levels. Methods: We have recruited 228 consecutive adult patients with NTM-PD from a prospective cohort study at the Keio University Hospital, who had no history of osteoporosis or osteoporosis-associated bone fracture but underwent dual-energy X-ray absorptiometry-based bone mineral density (BMD) evaluation from August 2017–September 2019. The E2 and 25OHD levels were measured in 165 patients with available stored serum samples. We performed multivariable logistic regression analyses for osteopenia and osteoporosis. Results: Osteoporosis (T-score ≤ − 2.5) and osteopenia (T-score − 1 to − 2.5) were diagnosed in 35.1% and 36.8% of patients with NTM-PD, respectively. Compared with the general population, the proportion of osteoporosis was significantly higher in 50–59-, 60–69-, and 70–79-year-old women with NTM-PD. Multivariable analysis revealed that older age (adjusted odds ratio [aOR] for 1-year increase = 1.12; 95% confidence interval [CI] = 1.07–1.18), female sex (aOR = 36.3; 95% CI = 7.57–174), lower BMI (aOR for 1 kg/m2 decrease = 1.37; 95% CI = 1.14–1.65), and chronic Pseudomonas aeruginosa (PA) infection (aOR = 6.70; 95% CI = 1.07–41.8) were independently associated with osteoporosis. Additionally, multivariable analysis in 165 patients whose serum E2 and 25OHD levels were measured showed that both low E2 levels (< 10 pg/mL) and lower 25OHD levels were independently associated with osteoporosis. Conclusions: Middle-aged/elderly women with NTM-PD have a higher prevalence of osteoporosis than the general population. BMD screening should be considered in NTM-PD, especially in older females with severe diseases such as chronic PA infection and lower BMI, and low serum E2 and 25OHD levels.

  • In vitro effects of diazabicyclooctane β-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex

    Misawa K., Nishimura T., Kashimura S., Enoki Y., Taguchi K., Uno S., Uwamino Y., Matsumoto K., Hasegawa N.

    International Journal of Antimicrobial Agents (International Journal of Antimicrobial Agents)  60 ( 5-6 )  2022年11月

    ISSN  09248579

     概要を見る

    Background: Mycobacterium abscessus complex (MABC) pulmonary disease is notoriously difficult to treat due to intrinsic resistance to many common antibiotics. MABC is β-lactam-resistant as it produces class A β-lactamases, such as blaMab, which are inhibited by diazabicyclooctane (DBO) β-lactamase inhibitors. Objectives: To investigate the microbiological effects of the combination of β-lactam and DBO β-lactamase inhibitors (relebactam and nacubactam) against MABC and determine if the effects are associated with the MABC subspecies and colony morphotype. Methods: The antimicrobial susceptibility of three type strains and 20 clinical isolates of MABC to the combination of seven β-lactams with relebactam or nacubactam was evaluated using broth microdilution checkerboard assays. For these strains, expression levels of blaMab were assessed using quantitative real-time polymerase chain reaction and genotypic diversity was evaluated using 18-locus variable number tandem repeat assay. Results: Relebactam and nacubactam lowered the minimum inhibitory concentrations of β-lactams, particularly imipenem, meropenem, and tebipenem, against MABC. There was no difference in efficacy of combination treatment between three subspecies, but rough morphotypes tended to be less susceptible than smooth morphotypes. There were no differences in blaMab expression levels and genotypic diversity between the morphotypes. Conclusions: The combination of β-lactam with relebactam or nacubactam improved the efficacy of β-lactams against all MABC subspecies, but higher concentrations of β-lactams were needed for rough morphotypes.

  • DOCK2 is involved in the host genetics and biology of severe COVID-19

    Namkoong H., Edahiro R., Takano T., Nishihara H., Shirai Y., Sonehara K., Tanaka H., Azekawa S., Mikami Y., Lee H., Hasegawa T., Okudela K., Okuzaki D., Motooka D., Kanai M., Naito T., Yamamoto K., Wang Q.S., Saiki R., Ishihara R., Matsubara Y., Hamamoto J., Hayashi H., Yoshimura Y., Tachikawa N., Yanagita E., Hyugaji T., Shimizu E., Katayama K., Kato Y., Morita T., Takahashi K., Harada N., Naito T., Hiki M., Matsushita Y., Takagi H., Aoki R., Nakamura A., Harada S., Sasano H., Kabata H., Masaki K., Kamata H., Ikemura S., Chubachi S., Okamori S., Terai H., Morita A., Asakura T., Sasaki J., Morisaki H., Uwamino Y., Nanki K., Uchida S., Uno S., Nishimura T., Ishiguro T., Isono T., Shibata S., Matsui Y., Hosoda C., Takano K., Nishida T., Kobayashi Y., Takaku Y., Takayanagi N., Ueda S., Tada A., Miyawaki M., Yamamoto M., Yoshida E., Hayashi R., Nagasaka T., Arai S., Kaneko Y., Sasaki K., Tagaya E., Kawana M., Arimura K., Takahashi K., Anzai T., Ito S., Endo A., Uchimura Y., Miyazaki Y., Honda T., Tateishi T., Tohda S., Ichimura N., Sonobe K., Sassa C.T., Nakajima J., Nakano Y., Nakajima Y., Anan R., Arai R., Kurihara Y., Harada Y., Nishio K.

    Nature (Nature)  609 ( 7928 ) 754 - 760 2022年09月

    ISSN  00280836

     概要を見る

    Identifying the host genetic factors underlying severe COVID-19 is an emerging challenge1–5. Here we conducted a genome-wide association study (GWAS) involving 2,393 cases of COVID-19 in a cohort of Japanese individuals collected during the initial waves of the pandemic, with 3,289 unaffected controls. We identified a variant on chromosome 5 at 5q35 (rs60200309-A), close to the dedicator of cytokinesis 2 gene (DOCK2), which was associated with severe COVID-19 in patients less than 65 years of age. This risk allele was prevalent in East Asian individuals but rare in Europeans, highlighting the value of genome-wide association studies in non-European populations. RNA-sequencing analysis of 473 bulk peripheral blood samples identified decreased expression of DOCK2 associated with the risk allele in these younger patients. DOCK2 expression was suppressed in patients with severe cases of COVID-19. Single-cell RNA-sequencing analysis (n = 61 individuals) identified cell-type-specific downregulation of DOCK2 and a COVID-19-specific decreasing effect of the risk allele on DOCK2 expression in non-classical monocytes. Immunohistochemistry of lung specimens from patients with severe COVID-19 pneumonia showed suppressed DOCK2 expression. Moreover, inhibition of DOCK2 function with CPYPP increased the severity of pneumonia in a Syrian hamster model of SARS-CoV-2 infection, characterized by weight loss, lung oedema, enhanced viral loads, impaired macrophage recruitment and dysregulated type I interferon responses. We conclude that DOCK2 has an important role in the host immune response to SARS-CoV-2 infection and the development of severe COVID-19, and could be further explored as a potential biomarker and/or therapeutic target.

  • The effect of the E484K mutation of SARS-CoV-2 on the neutralizing activity of antibodies from BNT162b2 vaccinated individuals

    Uwamino Y., Yokoyama T., Shimura T., Nishimura T., Sato Y., Wakui M., Kosaki K., Hasegawa N., Murata M.

    Vaccine (Vaccine)  40 ( 13 ) 1928 - 1931 2022年03月

    ISSN  0264410X

     概要を見る

    The reduced vaccine efficacy against the SARS-CoV-2 variant lineage B. 1.351 (beta variant) containing the E484K and N501Y mutations is well known. The E484K mutation in SARS-CoV-2 is thought to be responsible for weakened humoral immunity. Vaccine efficacy against the R.1 lineage, which contains the E484K mutation but not the N501Y mutation, is uncertain. Serum samples were collected from 100 healthy Japanese participants three weeks after receiving the second dose of the BNT162b2 vaccine, and serum neutralization antibody titers were measured against five SARS-CoV-2 variants. The geometric mean neutralization titers measured for the original and R.1 lineages were equivalent (91.90 ± 2.40 and 102.67 ± 2.28, respectively), whereas a low titer was measured for the beta variant (18.03 ± 1.92). Although further investigations with other variant strains and serum samples are essential, our results imply that the weakened humoral response is not caused solely by the E484K mutation. (UMIN000043340).

全件表示 >>

KOARA(リポジトリ)収録論文等 【 表示 / 非表示

全件表示 >>

研究発表 【 表示 / 非表示

  • 外国人留学生を対象とした結核感染調査

    西村知泰,森正明,牧野伸司,広瀬寛,和井内由充子,横山裕一,武田彩乃,畔上達彦,後藤伸子,河邊博史

    第116回日本内科学会総会・講演会 (名古屋) , 

    2019年04月

    ポスター発表

  • 肺MAC症の新規検査法

    西村 知泰

    第101回日本細菌学会関東支部総会 (東京) , 

    2018年11月

    シンポジウム・ワークショップ パネル(指名)

  • アスペルギルス沈降抗体陽性である肺Mycobacterium avium complex症患者の臨床的特徴

    鈴木翔二, 朝倉崇徳, 南宮湖, 岡森慧, 八木一馬, 鎌田浩史, 舩津洋平, 中野泰, 西村知泰, 石井誠, 海老原全, 別役智子, 長谷川直樹.

    第58回日本呼吸器学会学術講演会 (大阪) , 

    2018年04月

    ポスター発表

  • 大学生における先天性心疾患の管理状況

    牧野伸司, 和井内由充子, 武田彩乃, 畔上達彦, 広瀬寛, 西村知泰, 横山裕一, 河邊博史, 森正明.

    第115回日本内科学会年次学術講演会 (京都) , 

    2018年04月

    ポスター発表

  • 当大学医学部留学生に対するImmunization Recordの運用と考察

    武藤志保, 横山裕一, 弦巻美保, 齋藤圭美, 西村知泰, 森正明, 河邊博史.

    第55回全国大学保健管理研究集会 (宜野湾) , 

    2017年11月

    ポスター発表

全件表示 >>

競争的研究費の研究課題 【 表示 / 非表示

  • 医療従事者における新型コロナウイルスの感染状況調査

    2020年10月
    -
    2021年09月

    大和証券ヘルス財団, 西村知泰, 補助金,  研究代表者

  • 慶應義塾における新型コロナウイルス感染症対策

    2020年08月
    -
    2021年03月

    慶應義塾学事振興資金, 補助金,  研究代表者

  • 肺MAC症の病態における菌細胞壁脂質の役割

    2019年06月
    -
    2022年05月

    武田科学振興財団, 医学系研究助成, 補助金,  研究代表者

  • 肺非結核性抗酸菌症患者のゲノム情報に基づいた病態解明

    2019年04月
    -
    2022年03月

    文部科学省・日本学術振興会, 科学研究費補助金, 補助金,  研究分担者

  • 菌細胞壁脂質に着目した肺MAC症の病態解明

    2019年04月
    -
    2022年03月

    文部科学省・日本学術振興会, 科学研究費補助金, 補助金,  研究代表者

全件表示 >>

 

担当授業科目 【 表示 / 非表示

  • 感染症学

    2022年度

  • 感染症学

    2021年度

  • 感染症学

    2020年度

  • 現代社会と医学Ⅱ

    2019年度

  • 感染症学

    2019年度

担当経験のある授業科目 【 表示 / 非表示

  • 感染症学

    慶應義塾

    2018年04月
    -
    2019年03月

    通年, その他, 講義, 兼担

  • 現代社会と医学Ⅱ

    慶應義塾

    2018年04月
    -
    2019年03月

    通年, その他, 講義, 専任

 

社会活動 【 表示 / 非表示

  • 平成27年度外務省巡回医師団

    2016年02月
    -
    2016年03月
  • 平成26年度外務省巡回医師団

    2015年01月
    -
    2015年02月

所属学協会 【 表示 / 非表示

  • 日本免疫学会

     
  • 日本内科学会

     
  • 日本呼吸器学会

     
  • 日本呼吸器内視鏡学会

     
  • 日本感染症学会

     

全件表示 >>

委員歴 【 表示 / 非表示

  • 2016年04月
    -
    継続中

    評議員, 日本感染症学会